These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1760522)

  • 1. Calcitonin and metabolic alkalosis.
    Escanero JF; Elosegui LM; Cordova A; Pecondon A; Asin JJ; Beltran J; Otero W
    Biomed Pharmacother; 1991; 45(7):307-9. PubMed ID: 1760522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcitonin and the treatment of osteoporosis.
    Schneyer CR
    Md Med J; 1991 Jun; 40(6):469-73. PubMed ID: 1861574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of calcitonin in 20 patients suffering from postmenopausal osteoporosis. A proposal for a therapeutical scheme.
    Lanciani P; Porzio V; Cattani D
    Panminerva Med; 1991; 33(2):119-20. PubMed ID: 1923555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcitonin.
    Silverman SL
    Am J Med Sci; 1997 Jan; 313(1):13-6. PubMed ID: 9001161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D.
    Henriksen K; Byrjalsen I; Andersen JR; Bihlet AR; Russo LA; Alexandersen P; Valter I; Qvist P; Lau E; Riis BJ; Christiansen C; Karsdal MA;
    Bone; 2016 Oct; 91():122-9. PubMed ID: 27462009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postmenopausal osteoporosis: prevention and treatment with calcitonin.
    Prelevic GM; Adashi EY
    Gynecol Endocrinol; 1992 Jun; 6(2):141-7. PubMed ID: 1502932
    [No Abstract]   [Full Text] [Related]  

  • 7. Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.
    Plosker GL; McTavish D
    Drugs Aging; 1996 May; 8(5):378-400. PubMed ID: 8935399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
    Binkley N; Bolognese M; Sidorowicz-Bialynicka A; Vally T; Trout R; Miller C; Buben CE; Gilligan JP; Krause DS;
    J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcitonin therapy in osteoporotic syndromes.
    Avioli LV
    Rheum Dis Clin North Am; 1994 Aug; 20(3):777-85. PubMed ID: 7984789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women.
    Downs RW; Bell NH; Ettinger MP; Walsh BW; Favus MJ; Mako B; Wang L; Smith ME; Gormley GJ; Melton ME
    J Clin Endocrinol Metab; 2000 May; 85(5):1783-8. PubMed ID: 10843152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of postmenopausal osteoporosis with low doses of calcitonin and a calcitonin-anabolic combination].
    Szücs J; Horváth C; Kollin E; Szathmári M; Holló I
    Orv Hetil; 1992 Jun; 133(23):1415-8. PubMed ID: 1603585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological management of severe postmenopausal osteoporosis.
    Gaudio A; Morabito N
    Drugs Aging; 2005; 22(5):405-17. PubMed ID: 15903353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcitonin therapy in osteoporotic syndromes.
    Avioli LV
    J Am Med Womens Assoc (1972); 1990; 45(3):103-7. PubMed ID: 2186079
    [No Abstract]   [Full Text] [Related]  

  • 14. [Long-term local tolerability to intranasally administered salmon calcitonin in post-menopausal osteoporosis].
    Gariboldi LM; Bolla I; Baroni MC; Delsignore R; Passeri M; Barberis F
    Minerva Med; 1992 Dec; 83(12):827-31. PubMed ID: 1491763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs for prevention and treatment of postmenopausal osteoporosis.
    Treat Guidel Med Lett; 2002 Nov; 1(3):13-8. PubMed ID: 15529101
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of calcitonin treatment in postmenopausal osteoporosis.
    Wallach S
    Orthop Rev; 1992 Sep; 21(9):1034-42, 1130-1. PubMed ID: 1437254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current treatment concepts in primary osteoporosis: calcitonin].
    Ringe JD
    Schweiz Med Wochenschr; 1993 Nov; 123(47):2235-40. PubMed ID: 8272794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of calcitonin on urinary excretion of prostaglandins during menopause.
    Akgül C; Vural P; Canbaz M
    Gynecol Obstet Invest; 1998; 46(3):199-201. PubMed ID: 9736804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety concerns with the long-term management of osteoporosis.
    Reginster JY; Pelousse F; Bruyère O
    Expert Opin Drug Saf; 2013 Jul; 12(4):507-22. PubMed ID: 23614635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment.
    Gennari C; Nuti R; Agnusdei D; Camporeale A; Martini G
    Drug Saf; 1994 Sep; 11(3):179-95. PubMed ID: 7811400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.